newly diagnosed FLT3 non-mutated acute myeloid leukemia MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864
Conditions
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of AML (=20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible. 2. Suitability for intensive induction chemotherapy in the judgment of the investigator 3. Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated FLT3 screening laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type ratio. 4. Age = 18 years 5. Laboratory values that indicate adequate organ function assessed locally at the screening visit: • AST = 3 times ULN • Alanine aminotransferase (ALT) = 3 times ULN • Serum total bilirubin = 1.5 times ULN, unless in case of hyperbilirubinemia due to an isolated Gilbert syndrome • Estimated (by Cockcroft-Gault) creatinine clearance = 30ml/min 6. Written informed consent must be obtained prior to any screening procedures. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 452 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria
Exclusion criteria: 1. Central nervous system (CNS) leukemia 2. Therapy-related secondary AML 3. Isolated extramedullary leukemia 4. Prior therapy for leukemia or myelodysplasia with the following exceptions: a) Emergency leukapheresis b) Emergency treatment for hyperleukocytosis with hydroxyurea or low-dose cytarabine for = 7 days c) Cranial RT for CNS leukostasis (one dose only) d) Hematopoietic Growth factor/cytokine support e) Other supportive therapy including antibiotics at the discretion of the investigator 5. AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine) 6. Any investigational agent within 30 days or 5 half-lives, whichever is greater, prior to Day 1. An investigational agent is defined as an agent with no approved medical use in adults or in pediatric patients. 7. Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib) 8. Strong CYP3A4/5 enzyme inducing drugs unless they can be discontinued or replaced prior to enrollment. 9. Any other known disease or concurrent severe and/or uncontrolled medical condition (e.g., cardiovascular disease including congestive heart failure or active uncontrolled infection) that could compromise participation in the study. 10. Abnormal chest X-ray with corresponding clinical symptoms or findings that indicate an active infection, or other pulmonary conditions that are currently clinically significant. 11. Impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin. 12. Known confirmed diagnosis of HIV infection or active viral hepatitis (testing is not mandatory to exclude these viral infections). 13. Cardiovascular abnormalities, including any of the following: • History of MI, angina pectoris, CABG within 6 months prior to starting study treatment • Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) • Uncontrolled congestive heart failure • Left ventricular ejection fraction of <50%, • Poorly controlled hypertension 14. Pregnant or nursing (lactating) women 15. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 4 months after stopping medication. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. 16. Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for at least 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen. 17. Unwillingness or inability to comply with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine if the addition of midostaurin to standard induction and consolidation therapy, followed by single agent post-consolidation therapy improves EFS in patients with newly diagnosed FLT3-MN (SR<0.05) AML.;Secondary Objective: Key: determine if addition of midostaurin to standard induction + consolidation, followed by single agent post-consolidation improves OS in pts with newly diagnosed FLT3-MN AML 1. Compare CR + CRi with adequate recovery rate in the 2 treatment groups 2. Compare percentage of pts who reached MRD neg status in the 2 groups 3. Compare percentage of pts with MRD neg status in the postconsolidation phase in the 2 groups 4. Compare time to MRD neg bone marrow between the 2 treatment arms in the 2 groups 5. Compare DFS, as well as CIR and CID in the 2 groups 6. Compare time to CR or CRi 7. Compare time to neutrophil recovery in the 2 groups 8. Compare time to platelet recovery in the 2 treatment groups 9. Assess safety and tolerability of midostaurin in combination with chemotherapy and as monotherapy during post-consolidation 10.Characterize PK of midostaurin, CGP52421 and CGP62221 11.Assess impact of midostaurin on health related quality of life and AML symptom reduction;Primary end point(s): EFS defined as the time from randomization to failure to obtain a CR or CRi with adequate blood count recovery in induction, relapse after CR or CRi with adequate blood count recovery or death due to any cause, whichever occurs first as assessed by the investigator. ;Timepoint(s) of evaluation of this end point: Response disease assessment at end of each cycle and every 3 months during post-treatment follow-up Interim analysis at 12 and 20 months, final analysis at 39 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Key secondary endpoint: Overall survival is defined as the time from randomization to date of death due to any cause. 1. CR and CRi with adequate recovery rate according to the International Working Group (IWG) for AML (Cheson et al 2003, ELN 2017) as per investigator assessment. 2. Percentage of patients with MRD negative status. 3. Percentage of patients with MRD negative status during postconsolidation phase 4. Number of days from date of randomization to first documented MRD negative 5. DFS, as measured from the date of first CR or CRi with adequate blood count recovery to relapse or death from any cause, whichever occurs first. CIR is defined for patients with CR or CRi with adequate blood count recovery: time from achieving CR or CRi with adequate blood count recovery until onset of relapse. Patients without relapse are censored at the last adequate response assessment. Patients who died without relapse are counted as a competing cause of failure. CID is defined for patients with CR or CRi with adequate blood count recovery: time from achieving CR or CRi with adequate blood count recovery until death. Patients who did not die are censored at the last contact date. Patients who relapsed are counted as a competing cause of failure. 6. Number of days from date of randomization to first documented CR or CRi with adequate blood count recovery. 7. Number of days from the first day of a chemotherapy cycle to first day neutrophils =0.5 x 10^9/L. Number of days from day 1 of commencing induction therapy to first day neutrophils =1.0 x 10^9/L. 8. Number of days from the first day of a chemotherapy cycle to first day platelets =50 x 10^9/L. Number of days from day 1 of commencing induction therapy to first day platelets =100 x10^9/L. 9. Frequency/severity of AEs, and laboratory abnormalities. 10. Plasma concentrations and pharmacokinetic parameters for midostaurin, CGP52421 and CGP62221. 11. Change from baseline | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Norway, Poland, Portugal, Spain, Switzerland, Taiwan, Turkey, United States
Contacts
Public ContactClinical Trial Information Desk
Novartis Farma - Produtos Farmacêuticos, S.A.
Outcome results
None listed